Credit Intelligence (ASX:CI1): the biggest beneficiary from buy now, pay later — profitable and undervalued
ASX-listed debt restructuring specialist Credit Intelligence (ASX:CI1) is uniquely positioned to tackle an oncoming new age…
MoneyMe (ASX:MME) and the success of tech-focused lending
ASX-listed fintech stock MoneyMe (ASX:MME) has found success in the increasingly crowded Australian market by focusing…
Douugh (ASX:DOU): The best thing since sliced bread?
The story of the ASX fintech newcomer Douugh (ASX:DOU) is a tale of resilience.
MyFiziq (ASX:MYQ) is poised to disrupt the $45B medical imaging market
MyFiziq's (ASX:MYQ) advanced human imaging technology is a game-changer for the future of healthcare.
An extraordinary clash of conditions in investment markets
Investment markets have a host of both positive and negative factors fighting for supremacy.
Little Green Pharma (ASX:LGP) and the future of medicinal cannabis
Little Green Pharma's (ASX:LGP) recent partnership with HIF puts a spotlight on medicinal cannabis treatments.
What do investors stand to gain from Australia’s clinical trial landscape?
As healthcare giants scramble to create a COVID-19 vaccine, there is a growing interest in clinical trials and how exactly they work.
Renascor Resources (ASX:RNU): Poised to capture the gold rise
It's no secret that COVID-19 has caused investors to flock to gold stocks, seeing the precious…
Will Douugh (ASX:DOU) rise, or is it toast?
ASX newcomer Douugh (ASX:DOU) is one of the fastest-moving fintech stocks on the local share market,…
Cann Global (ASX:CGB): Disrupting the lucrative Australian cannabis market
The Australian cannabis and hemp industries have largely taken a back seat in 2020 as COVID-19…